title: Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.
abstract: BACKGROUND
  We conducted a feasibility study on docetaxel/capecitabine/cisplatin (DCX) with chemoradiotherapy as adjuvant treatment for gastric cancer patients.
  
  
  METHODS
  Patients were scheduled to receive 2 cycles of DCX, followed by 50.4 Gy plus capecitabine as radiotherapy, followed by an additional 2-DCX cycles.
  
  
  RESULTS
  From the 40 enrolled patients, 26 (65%) completed treatment as per protocol and 14 (35%) discontinued with the treatment (patients' refusal: n=6; adverse events: n=8). There were 2 toxic deaths. Grade >3 toxicity was 12.1% before and 13.3% after chemoradiotherapy. Disease progression was documented in 11 (27.5%) patients.
  
  
  CONCLUSIONS
  No further development of this regimen is justified on the basis of poor tolerability in patients.
authors.affiliation: The Hellenic Oncology Research Group (HORG), Athens, Greece.
authors.forename: Zacharenia
authors.initials: Z
authors.lastname: Saridaki
authors.forename: Georgia
authors.initials: G
authors.lastname: Lambrodimou
authors.forename: Stefanos
authors.initials: S
authors.lastname: Kachris
authors.forename: Paris
authors.initials: P
authors.lastname: Makrantonakis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Boukovinas
authors.forename: Aris
authors.initials: A
authors.lastname: Polyzos
authors.forename: Athanasios
authors.initials: A
authors.lastname: Anagnostopoulos
authors.forename: Athanasios
authors.initials: A
authors.lastname: Athanasiadis
authors.forename: Dimitris
authors.initials: D
authors.lastname: Stoltidis
authors.forename: Vassilis
authors.initials: V
authors.lastname: Georgoulias
authors.forename: John
authors.initials: J
authors.lastname: Souglakos
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D059186:Chemoradiotherapy, Adjuvant / Q000379:methods; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D005743:Gastrectomy; D006323:Heart Arrest / Q000139:chemically induced; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D018805:Sepsis / Q000209:etiology; D013274:Stomach Neoplasms / Q000628:therapy*; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D002945:Cisplatin; D005472:Fluorouracil